# Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy

> **NCT07255781** · — · WITHDRAWN · sponsor: **University of California, San Diego**

## Conditions studied

- Psoriasis (PsO)
- PsA (Psoriatic Arthritis)
- NAFLD (Nonalcoholic Fatty Liver Disease)

## Interventions

- **DRUG:** Guselkumab Prefilled Syringe [Tremfya]

## Key facts

- **NCT ID:** NCT07255781
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-11-30
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The sponsor determined that enrollment would not meet their expectations and decided to withdraw the study.
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07255781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07255781, "Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07255781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*